Immix Biopharma prices 11,363,637-share offering at USD 11.00 per share for USD 125 million gross proceeds

Bitget2026/09/29 11:05

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Immix Biopharma priced an underwritten offering of 11,363,637 common shares at USD 11.00 each.
Gross proceeds expected at USD 125 million before underwriting discounts, commissions, and offering expenses.
Closing expected on or about Sept. 30, 2026, subject to customary conditions.
Net proceeds earmarked for NXC-201 development, working capital, and general corporate purposes.
J.P. Morgan is sole book-running manager.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immix Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609290705PRIMZONEFULLFEED9835887) on September 29, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Immix Biopharma prices 11,363,637-share offering at USD 11.00 per share for USD 125 million gross proceeds

You may also like

Crypto prices